Ignacio Durán - Concepedia

Author

Ignacio Durán

Hospital Universitario Virgen del Rocío ORCID

Also Known As

C. Cervera, Duran I, Duran, Ignacio, Durán I, I DURAN, I Duran, I Durán, I Oreja Duran, I. Duran, I. Durán

345

Publications

16.6K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Virgen del Rocío Institut Gustave Roussy Instituto de Investigación Marqués de Valdecilla Hospital Universitario 12 De Octubre Institut Català d'Oncologia

About

Ignacio Durán is an author at Hospital Universitario Virgen del Rocío specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	57	8.1K
2	Health Sciences	14	15	515
3	Public Health	3	3	153
4	Nursing	1	1	38
5	Cell Biology	1	1	17

Ignacio Durán

105

Publications

14.2K

Citations

H-Index

Page 1

	Year	Citations
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, The Lancet UrologyGenitourinary CancerMedicineFirst-line TreatmentCancer Treatment	2016	2.2K
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, The Lancet UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineCancer Treatment	2017	1.4K
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma Yohann Loriot, Andrea Necchi, Se Hoon Park, New England Journal of Medicine	2019	1.3K
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde, New England Journal of Medicine	2021	1.1K
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, New England Journal of Medicine	2024	764
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Robert J. Motzer, Brian I. Rini, David F. McDermott, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint Inhibitor	2019	763
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida, Nature Medicine UrologyBiomarker AnalysisGenitourinary CancerMedicineCancer Treatment	2019	555
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, The Lancet Oncology Surgical OncologyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2020	485
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, European Urology	2020	384
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Ignacio Durán, Jeremy Kortmansky, Deepti Singh, British Journal of Cancer	2006	316

Page 1